Attacking Cancer’s Key Mechanisms to Treat Metastatic Pancreatic Cancer
A clinical trial for patients with metastatic pancreatic cancer uses the new drug SM-88 in combination with other agents, to attack the tumor metabolism.
GENERATE Trial Expands Eligibility
Dr. Sapna Syngal explains the expanded eligibility standards for the GENERATE Study for genetic testing of pancreatic cancer patients and relatives.
PARP Inhibitors in Pancreatic Cancer
Tanios Bekaii-Saab, M.D., of the Mayo Clinic in Phoenix, AZ, explains the importance of research into treatment with PARP inhibitors…
IARC Identifies Eight Additional Cancer Sites Linked to Overweight and Obesity
Based on a systematic review of the published scientific literature, the Working Group for IARC Handbooks of Cancer Prevention Volume…
Pancreatic Cancer Trial to Make Tumors More Sensitive to Treatment
The trial, which launches in the UK today, will treat pancreatic cancer patients whose cancer has grown too big to…
